Medicine and Dentistry
Patient
100%
Therapeutic Procedure
70%
Immunoglobulin
64%
Polyradiculoneuropathy
55%
Guillain-Barré Syndrome
30%
Plasma Exchange
27%
Randomized Controlled Trial
25%
Neuropathy
23%
Beta1a Interferon
22%
Neurologic Disease
22%
Systematic Review
18%
Diagnosis
17%
Neurofibromatosis Type I
14%
Fluorodeoxyglucose
14%
Positron Emission Tomography
14%
Multifocal Motor Neuropathy
13%
Disease
12%
Disability
12%
Analysis
9%
Nerve Biopsy
9%
Quality of Life
9%
Nerve Block
9%
Person
9%
Neuromuscular Disease
9%
Syndrome
9%
Symptom
8%
Infection
8%
Polyneuropathy
8%
Plexiform Neurofibroma
8%
Malignant Peripheral Nerve Sheath Tumor
8%
Immunoabsorption
8%
Infusion
8%
Neurology
8%
Health
7%
Bell's Palsy
7%
Clinical Research
7%
DeJerine-Sottas Disease
7%
Health Care Provider
7%
Health Care
7%
Cohort Effect
7%
Disease Activity
7%
Prospective Study
7%
Biopsy Technique
7%
Immunity
7%
Dyspnea
7%
COVID-19
7%
Post-COVID-19
7%
Follow up
6%
Medical Research
5%
Chromatography
5%
Neuroscience
Guillain-Barre Syndrome
69%
Randomized Controlled Trial
52%
Intravenous Immunoglobulin
47%
Interferon Beta 1a
26%
Corticosteroid
24%
Neuromuscular Disorder
16%
Antibodies
16%
Neuritis
15%
Brain-Derived Neurotrophic Factor
14%
Nervous System Disorder
14%
CD8
14%
Peripheral Nerve
14%
Interferon
9%
Methotrexate
9%
Magnetic Resonance Imaging
9%
Nervous System Regeneration
8%
Steroids
7%
Polyneuropathy
7%
Prednisolone
7%
Primary Progressive Multiple Sclerosis
7%
2-Deoxy-D-Glucose
7%
Cyclophosphamide
7%
Ciclosporin
7%
CD4
5%
Nursing and Health Professions
Patient
16%
Motor Neuron Disease
14%
Clinical Practice
14%
Clinical Outcome
9%
Immunoadsorption
8%
Guillain Barre Syndrome
7%
Cost Utility Analysis
7%
Standard
7%
Epidemiology
7%
Control
7%
Cochrane Library
7%
